Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.

Trial Details

NCT ID
NCT05287945
Phase
PHASE1 / PHASE2
Sponsor
Oncorena AB
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Orellanine
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Houston, Texas, United States|29.76328,-95.36327
  • Lisbon, Portugal|38.72509,-9.1498
  • Stockholm, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • Has provided written informed consent.
  • Has a diagnosis of histologically confirmed advanced ccRCC or pRCC. No conventional therapy is available or considered appropriate by the treating …
  • For patients in the expansion portion of the study only: Measurable disease per RECIST version 1.1 criteria.
  • ECOG performance status of 0 - 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →